Citations

Clear

9383 citation(s) found for "Thomas, PS".

Sex and sex hormonal regulation of the atrial inward rectifier potassium current (IK1): insights into potential pro-arrhythmic mechanisms
Giammarino, Lucilla , Matas, Lluis , Alerni, Nicolò , Vashanthakumar, Varjany, Nimani, Saranda , Barbieri, Miriam , López, Rubén , Louradour, Julien , Hof, Thomas , Maguy, Ange , Schotten, Ulrich , Odening, Katja E. , Auricchio, Angelo , Schotten, Ulrich , Odening, Katja E , Horváth, András , Bains, Sahej , Ördög, Balázs , Conte, Giulio

Mayo Clinic

Cardiovascular Research | April 24, 2025 | Volume: 121 | Issue: 8 | Pages: 1215-1227

10.1093/cvr/cvaf074 | PMID 40272446 Get It

Abstract Aims Pronounced sex-differences are known in the incidence of atrial fibrillation (AF). In this study, we aimed to investigate the atrial electrophysiological properties that may underlie sex-differences in AF incidence in the younger population, focusing on IK1, a cardiac ion current important for action potential (AP) stability and triggered activity. Methods and results We assessed sex-differences in P-wave morphology in 12-lead ECG in healthy young New Zealand White rabbits. Males presented longer PWD and larger P-wave area compared to females. Patch-clamp experiments were performed in isolated rabbit atrial cardiomyocytes (CMs). Male atrial CMs presented higher delayed after depolarizations (DAD) incidence, amplitude, and area under the curve (AUC) than females, potentially facilitating the presence of atrial triggered activity in males. Male atrial CMs showed a less hyperpolarized resting membrane potential (RMP), a 50% smaller IK1, and a 26% reduction in Kir2.1 protein expression, a pore forming subunit of IK1, than females. Dihydrotestosterone (DHT) effects were investigated acutely and semi-chronically ex vivo. Experiments showed that the sex-difference in IK1 could be mimicked by DHT. In female atrial CMs, acute and semi-chronic (24 h) DHT administration reduced IK1. In the presence of a PKC-inhibitor, DHT-mediated IK1 reduction was not observed in atrial female CMs, suggesting it to be PKC-mediated. Chronic DHT-effects were investigated in vivo in female rabbits after hormone-releasing pellet implantation. After 2 weeks, animals showed a significantly prolonged and larger P-wave, a smaller atrial IK1 and a trend towards an increased DAD amplitude and AUC. Conclusion Sex impacts on atrial electrophysiology, leading to sex-differences in P-wave morphology, triggered activity, RMP, and IK1. These sex-differences can be mimicked by sex hormone-treatment, suggesting that sex hormones—particularly DHT—play a pivotal role in mediating sex-differences in atrial electrophysiology. Such sex-differences might impact on the propensity to develop AF, particularly in the younger population.
A practical guide to the implementation of AI in orthopaedic research—Part 7: Risks, limitations, safety and verification of medical AI systems
Winkler, Philipp W. , Senorski, Eric Hamrin , Tischer, Thomas , Herbst, Elmar , Pareek, Ayoosh , Musahl, Volker , Oettl, Felix C. , Group, ESSKA Artificial Intelligence Working, Hamrin Senorski, Eric , Longo, Umile Giuseppe , Samuelsson, Kristian , Zsidai, Bálint , Pruneski, James A. , Hirschmann, Michael T. , Ley, Christophe , Oeding, Jacob F. , Oettl, Felix C. , Longo, Umile Giuseppe , Samuelsson, Kristian , Feldt, Robert , Group, ESSKA Artificial Intelligence Working

Mayo Clinic

Journal of Experimental Orthopaedics | April 24, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/jeo2.70247 | PMID 40276496 Get It

AbstractArtificial intelligence (AI) has been influencing healthcare and medical research for several years and will likely become indispensable in the near future. AI is intended to support healthcare professionals to make the healthcare system more efficient and ultimately improve patient outcomes. Despite the numerous benefits of AI systems, significant concerns remain. Errors in AI systems can pose serious risks to human health, underscoring the critical need for safety, as well as adherence to ethical and moral standards, before these technologies can be integrated into clinical practice. To address these challenges, the development, certification, and deployment of medical AI systems must adhere to strict and transparent regulations. The European Commission has already established a regulatory framework for AI systems by enacting the European Union Artificial Intelligence Act. This review article, part of an AI learning series, discusses key considerations for medical AI systems such as reliability, accuracy, trustworthiness, lawfulness and legal compliance, ethical and moral alignment, sustainability, and regulatory oversight.Level of EvidenceLevel V.
Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy
Trinka, Eugen , Wirrell, Elaine , Abdulla, Fatema , Albaradie, Raidah , Auvin, Stéphane , Singh, Mamta Bhushan , Blumenfeld, Hal , Fressola, Alicia Bogacz , Caraballo, Roberto , Charway‐Felli, Augustina , Ezeala‐Adikaibe, Birinus , Gule, M. V., Higurashi, Norimichi , Jansen, Floor E. , Kahane, Philippe , Vinayan, Kollencheri Puthenveettil , Lagae, Lieven , Lim, Kheng Seang , Lizcano, Angélica , McGonigal, Aileen , Perez‐Gosiengfiao, Katerina Tanya, Ryvlin, Philippe , Stefan, H. , Tatum, William O. , Tripathi, Manjari, Yacubian, Elza Márcia Targas , Wiebe, Samuel , Wilmshurst, Jo M. , Zhou, Dong , Cross, J. Helen , Beniczky, Sándor , Trinka, Eugen , Wirrell, Elaine C , Al Baradie, Raidah , Auvin, Stéphane , Singh, Mamta Bhushan , Blumenfeld, Hal , Bogacz Fressola, Alicia , Caraballo, Roberto H , Cendes, Fernando , Felli, Augustina Charway , Cook, Mark J , Craiu, Dana , Frauscher, Birgit , French, Jacqueline , Higurashi, Norimichi , Ikeda, Akio , Jansen, Floor E , Jobst, Barbara , Kahane, Philippe , Kishk, Nirmeen , Khoo, Ching Soong , Lagae, Lieven , Lim, Kheng-Seang , Lizcano, Angelica , McGonigal, Aileen , Ryvlin, Philippe , Specchio, Nicola , Sperling, Michael R , Tatum, William O , Yacubian, Elza Márcia , Wiebe, Samuel , Wilmshurst, Jo M , Zhou, Dong , Cross, Helen J , Alonso‐Vanegas, Mario , Carreño, Mar , Cendes, Fernando , Cook, Mark , Frauscher, Birgit , French, Jacqueline A. , Jobst, Barbara C. , Specchio, Nicola , Sperling, Michael R. , Tripathi, Manjari

Mayo Clinic

Epilepsia | April 23, 2025 | Volume: 66 | Issue: 6 | Pages: 1804-1823

10.1111/epi.18338 | PMID 40264351 Get It

Abstract The International League Against Epilepsy (ILAE) has updated the operational classification of epileptic seizures, building upon the framework established in 2017. This revision, informed by the implementation experience, involved a working group appointed by the ILAE Executive Committee. Comprising 37 members from all ILAE regions, the group utilized a modified Delphi process, requiring a consensus threshold of more than two thirds for any proposal. Following public comments, the Executive Committee appointed seven additional experts to the revision task force to address and incorporate the issues raised, as appropriate. The updated classification maintains four main seizure classes: Focal, Generalized, Unknown (whether focal or generalized), and Unclassified. Taxonomic rules distinguish classifiers, which are considered to reflect biological classes and directly impact clinical management, from descriptors, which indicate other important seizure characteristics. Focal seizures and those of unknown origin are further classified by the patient's state of consciousness (impaired or preserved) during the seizure, defined operationally through clinical assessment of awareness and responsiveness. If the state of consciousness is undetermined, the seizure is classified under the parent term, that is, the main seizure class (focal seizure or seizure of unknown origin). Generalized seizures are grouped into absence seizures, generalized tonic–clonic seizures, and other generalized seizures, now including recognition of negative myoclonus as a seizure type. Seizures are described in the basic version as with or without observable manifestations, whereas an expanded version utilizes the chronological sequence of seizure semiology. This updated classification comprises four main classes and 21 seizure types. Special emphasis was placed on ensuring translatability into languages beyond English. Its aim is to establish a common language for all health care professionals involved in epilepsy care, from resource‐limited areas to highly specialized centers, and to provide accessible terms for patients and caregivers.
Rare Extra‐Axial Chordoma of the Anteromedial Thigh: A Case Report
Tibbo, Meagan E. , Mysore, Nishad , Jose, Jean , Temple, H. Thomas , Rosenberg, Andrew E.

Mayo Clinic

Clinical Case Reports | April 23, 2025 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/ccr3.70341 | PMID 40270777 Get It

ABSTRACT Chordomas are rare notochordal malignancies typically occurring in the axial skeleton. Less than 100 extra‐axial chordomas have been reported. We describe a unique chordoma of the anteromedial thigh. The clinical presentation of extra‐axial chordomas is highly variable; thus, recognizing this entity in the differential diagnoses of extra‐axial bone/soft tissue tumors is important.
Abstract 7344: Family history of hematologic malignancy and prognosis across lymphoma subtypes: Novel association with poor outcomes in follicular lymphoma
Cholack, George , Mwangi, Raphael , Hinder, Verena, Griffen, Rosalie, Robinson, Dennis P. , Feldman, Andrew L., Ansell, Stephen M. , Thompson, Carrie A. , Novak, Anne J. , Cholack, George A , Habermann, Thomas M. , Hinder, Verena, Feldman, Andrew L. , Witzig, Thomas E. , Link, Brian K. , Wang, Yucai , Slager, Susan L. , Maurer, Matthew J. , Cerhan, James R.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7344-7344

10.1158/1538-7445.am2025-7344 Get It

Abstract Family history of hematologic malignancy (FHHM) is an established risk factor for developing lymphoma, but studies examining associations between self-reported FHHM and lymphoma prognosis during the recent treatment era are limited. Utilizing a prospective cohort study, we evaluated associations between FHHM and prognosis for common lymphoma subtypes, including diffuse large B-cell (DLBCL), follicular (FL), marginal zone (MZL), mantle cell (MCL), Hodgkin (HL), and T-cell (TCL) lymphomas. We used the Mayo Clinic component of the Molecular Epidemiology Resource, a prospective cohort study of newly diagnosed lymphoma patients enrolled from 2002 to 2015. Self-reported FHHM (HL, NHL, leukemia, or multiple myeloma) in a first-degree relative was obtained via questionnaire. Primary outcomes were overall survival (OS) and event-free survival (EFS; time from diagnosis to disease progression, initiation of second-line therapy, or all-cause death). Secondary outcomes were failure to achieve 24 months of event-free survival (EFS24; associated with aggressive disease and poor outcomes) and lymphoma-specific survival (LSS; time from diagnosis to death from lymphoma or lymphoma treatment-related complications). We used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for the association of FHHM with OS, EFS, and LSS, and logistic regression to estimate odds ratios (ORs) and 95% CI for the association with failure to achieve EFS24. All models were adjusted for sex and a lymphoma subtype specific prognostic index. The cohort consisted of 650 DLBCL, 679 FL, 291 MZL, 178 MCL, 254 HL, and 196 TCL patients. The prevalence of FHHM ranged from 9.7% in TCL to 14% in FL. FHHM was not associated with OS in any subtype, but MCL patients with FHHM showed an inferior EFS (HR=1.70, 95% CI 1.02-2.85; p=0.04). For EFS24, FHHM was associated with failure to achieve EFS24 only in FL (OR=1.57, 95% CI 0.99-2.48; p=0.05). Similarly, FHHM was associated with inferior LSS in FL patients (HR=1.98, 95% CI 1.11-3.53; p=0.02). In a treatment subgroup analysis of FL patients, the FHHM associations with failure to achieve EFS24 (OR=2.48, 95% CI 1.04-5.74; p=0.04) and inferior LSS (HR=2.68, 95% CI 1.09-6.58; p=0.03) strengthened among those treated with frontline immunochemotherapy (IC). In summary, there were no evidence of associations between FHHM and OS across lymphoma subtypes, but MCL patients with FHHM displayed inferior EFS. FL patients with FHHM were more likely to not achieve EFS24 and to ultimately die of their lymphoma or a lymphoma treatment-related complication. This finding was stronger in more aggressive FL requiring frontline IC. This novel finding would suggest that genetic or environmental factors associated with FHHM may underlie pathways that impact disease aggressiveness and early clinical failure in FL. Citation Format: George Cholack, Raphael Mwangi, Thomas M. Habermann, Verena Hinder, Rosalie Griffen, Dennis Robinson, Andrew L. Feldman, Thomas E. Witzig, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan. Family history of hematologic malignancy and prognosis across lymphoma subtypes: Novel association with poor outcomes in follicular lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7344.
Abstract 1666: Novel endoxifen-based proteolysis targeting chimera (PROTAC) small molecules synergize with olaparib and exhibit potent antitumor activity in triple negative breast cancer through induction of DNA damage
Thulung, Lucy Rai, Bruinsma, Becky, Welch, Baustin M. , Wyatt, Samuel, Rodman, Esther , Bhattacharya, Sayantani , Hawse, John R. , Schellenberg, Matthew J. , Dekhne, Aamod S. , Jayaraman, Swaathi , Thulung, Lucy Rai , Wyatt, Samuel, Bhattacharya, Sayantani, Caulfield, Thomas R. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1666-1666

10.1158/1538-7445.am2025-1666 Get It

Abstract Breast cancer (BC) is the most common cancer diagnosed in American women. The majority of breast cancers express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). However, 15-20% lack expression of all three and are called triple-negative breast cancer (TNBC). TNBC accounts for a disproportionately large amount of morbidity and mortality due to its aggressive nature and the paucity of effective adjuvant maintenance therapy, driving an urgent need for novel therapeutics. Z-endoxifen (ENDX) is a potent tamoxifen metabolite that dually targets ERα and protein kinase C beta I (PKCβI). We recently described next-generation molecules, the first-in-class endoxifen-PROTAC (ENDX-PROTAC) compounds which incorporate ENDX as the warhead and cereblon (CRBN) as the E3 ubiquitin ligase recruitment moiety (Jayaraman 2024, SABCS). We used the PRISM screen of over 900 cancer cell lines to determine that ENDX-PROTACs have broad antitumor activity in both TNBC and ER+ breast cancer in addition to, leukemia, pancreatic, lymphoma, lung, melanoma, and ovarian cancer cells, among others. ENDX-PROTACs primarily target a key translation termination factor, G to S phase transition 1 (GSPT1). Here, we demonstrate for the first time that these compounds also cause marked DNA damage. The lead compounds of this series, EPrC-007 and EPrC-009 demonstrated potent anti-proliferative effects in MDA-MB-231, BT549, and MDA-MB-436 TNBC cell lines. EPrC-007 induced substantial DNA double strand breaks in MDA-MB-231 cells as assessed by γ-H2AX Western blotting. Interrogation of DNA repair pathways revealed activation of ATM/CHK2 and downregulation of ATR/CHK1, suggesting inhibition of DNA repair as a potential mechanism. Additionally, EPrC-007 also induced γ-H2AX foci in MDA-MB-231 and BT549 cells, but not in the MCF10A normal breast tissue cell line, suggesting selective anti-tumor activity. Since we suspect that EPrC-007 blocks DNA repair machinery, we next sought to determine if these molecules would synergize with DNA damaging agents or other DNA repair inhibitors. Promisingly, EPrC-007 demonstrated remarkable synergy with olaparib (poly-(ADP-ribose) polymerase (PARP) inhibitor), hydroxyurea (ribonucleotide reductase inhibitor), and cisplatin (direct DNA damaging agent), but not camptothecin (topoisomerase I inhibitor). Importantly, only olaparib co-treatment demonstrated synergy in the PARP- and PROTAC-resistant HCC1143 TNBC cell line. Furthermore, the combination of EPrC-007 with olaparib induced markedly more γ-H2AX foci than either agent alone, confirming synergy at the DNA damage level. Taken together, our studies demonstrate the remarkable potential of ENDX-PROTACs in the single-agent setting as well as in combination with PARP inhibitors. Citation Format: Aamod S. Dekhne, Swaathi Jayaraman, Lucy Rai Thulung, Becky Bruinsma, Baustin M. Welch, Samuel Wyatt, Esther P. Rodman, Sayantani Bhattacharya, Thomas R. Caulfield, John R. Hawse, Matthew J. Schellenberg, Matthew P. Goetz. Novel endoxifen-based proteolysis targeting chimera (PROTAC) small molecules synergize with olaparib and exhibit potent antitumor activity in triple negative breast cancer through induction of DNA damage [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1666.
Abstract 2282: Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity
Williams, Jacob , Jahagirdar, Om , Li, Jingmei, Godbole, Devika , Dorling, Leila , Dennis, Joe, Kushi, Larry, Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Zheng, Wei , Huo, Dezheng , Easton, Douglas F. , Chatterjee, Nilanjan , Kraft, Peter, Wong, W. W., Zhu, Qianqian , Ahearn, Thomas U., Li, James , Zanti, Maria , Jia, Guochong , Hu, Qiang , Brandenburg, Jean‐Tristan , Li, Yàn , Ho, Weang-Kee , Miranda, Patricio , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Martin Jinye , Zhang, Yan , John, Esther M. , Torres-Mejı́a, Gabriela , Kushi, Larry, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Ziv, Elad , Fejerman, Laura , Chatterjee, Nilanjan , García‐Closas, Montserrat , Wong, Wendy, Michailidou, Kyriaki , Dutta, Diptavo , Ahearn, Thomas U. , Zhang, Haoyu

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2282-2282

10.1158/1538-7445.am2025-2282 Get It

Abstract Introduction: Breast cancer genome-wide association studies (GWAS) have identified over 200 susceptibility loci, many replicated in diverse populations. However, cross-ancestry evaluation of breast cancer genetic architecture remains limited. We examined breast cancer genetic architecture using GWAS summary results from European (EUR; cases (ca) = 188,474, controls (co) = 96,201), East Asian (EAS; ca = 20,393, co = 86,329), African American (AA; ca = 9,235, co = 10,184), and US Hispanic/Latina and Latin American (H/L; ca = 2,396, co =7,468) studies. Methods: GWAS results were derived from the Breast Cancer Association Consortium, the African Ancestry Breast Cancer Genetics Consortium (AABCG), Biobank Japan, and a meta-analysis of five studies of H/L women with breast cancer. Linkage disequilibrium (LD) scores were generated for EUR, EAS, and AMR using the 1000 Genomes Project, while AA LD scores were derived from a subset of AABCG controls. Heritability was estimated for each ancestry group using LD score regression. Genetic correlations between populations were assessed via Popcorn. Polygenicity was analyzed using GENESIS; however, due to the limited sample size in the H/L studies, these estimates were restricted to AA, EAS, and EUR. Enrichment of heritability across regulatory elements was evaluated using stratified LD score regression across all populations. Results: The logit-scale heritability and corresponding standard error (SE) were 0.466 (0.066) for EAS, 0.501 (0.050) for EUR, 0.588 (0.360) for H/L, and 0.614 (0.095) for AA. The estimated number of independent susceptibility loci was 4,446 for EAS, 5,235 for EUR, and 8,308 for AA. Using a clumping and thresholding approach, an optimal set of common variants were projected to explain 38.6% (EUR), 39.4% (EAS), and 26.2% (AA) of genetic variance for samples of 100,000 cases and 100,000 controls with AUCs from corresponding estimated polygenic risk scores (PRSs) of 0.621 (EUR), 0.634 (EAS), and 0.611 (AA). Genetic correlations were strongest between EUR and EAS (ρ = 0.79, SE = 0.08) and EUR and H/L (ρ = 0.68, SE = 0.21), and weakest between AA and EAS (ρ = 0.42, SE = 0.14) and AA and H/L (ρ = 0.26, SE = 0.24). Among 73 genomic features, we found significant (P < 0.05/73) enrichment in heritability in EUR for ‘ancient promoter’ regions, transcription factor binding sites, H3K4me3, ‘super-enhancers’, H3K4me1, H3K27ac; in EAS for ‘super-enhancers’; and in AA for H3K27ac. No genomic features were significantly enriched in H/L, likely due to limited power. Conclusion: These findings suggest a shared breast cancer genetic architecture across diverse populations, as well as the potential for a similar level of breast cancer risk stratification by PRS in these populations. Expanding GWAS in underrepresented populations is essential to improve genetic risk predictions and foster equitable cancer prevention. Citation Format: James L. Li, Maria Zanti, Jacob Williams, Om Jahagirdar, Guochong Jia, Qiang Hu, Jean-Tristan Brandenburg, Li Yan, Weang-Kee Ho, Jingmei Li, José P. Miranda, Devika Godbole, Julie-Alexia Dias, Leila Dorling, Wenlong C. Chen, Nicholas Boddicker, Ying Wang, Alicia Martin, Martin J. Zhang, Yan Zhang, Joe Dennis, Esther M. John, Gabriela Torres-Mejia, Larry Kushi, Jeffrey Weitzel, Susan L. Neuhausen, Luis Carvajal-Carmona, Christopher Haiman, Elad Ziv, Laura Fejerman, Wei Zheng, Dezheng Huo, Douglas Easton, Nilanjan Chatterjee, Peter Kraft, Montserrat Garcia-Closas, Wendy Wong, Kyriaki Michailidou, Qianqian Zhu, Diptavo Dutta, Thomas U. Ahearn, Haoyu Zhang. Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2282.
Abstract 3583: The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology
Kraft, Peter, O’Meara, Ellen S. , Rohan, Thomas, Neuhouser, Marian L, Vachon, Celine M, Haiman, Christopher, White, Emily , Lee, I‐Min , Gaudet, Mia M. , Chatterjee, Nilanjan , Freeman, Laura E. Beane , Palmer, Julie R. , Genkinger, Jeanine M. , Lacey, James V. , Teras, Lauren R. , Visvanathan, Kala , Milne, Roger L. , Chen, Yu , Eliassen, A. Heather , Kitahara, Cari M. , O’Brien, Katie M. , Anderson, Garnet L. , Campbell, Archie I , Fortner, Renée T. , Lagerros, Ylva Trolle , Sandin, Sven , García‐Closas, Montserrat

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3583-3583

10.1158/1538-7445.am2025-3583 Get It

Abstract Breast cancer risk assessment tools are widely used in clinical practice to guide decisions regarding screening timing and modality, lifestyle interventions, genetic testing, preventive therapy, and risk-reducing surgery. Although a number of tools designed for the general population are used in practice, they face a series of challenges including: (i) modest discriminatory ability due to lack of a unified model that flexibly incorporates a comprehensive set of risk factors; (ii) inability to produce subtype-specific risk estimates, relevant for tailoring screening and/or preventive strategies (e.g. prophylactic endocrine therapy that is effective only for hormone receptor positive tumors); (iii) lack of data from diverse populations to build models that work well for all women; and, (iv) scarcity of opportunities for comparative validation of different models. The Breast Cancer Risk Prediction Project (BCRPP), a collaboration currently including 20 prospective cohorts from the National Cancer Institute’s Cohort Consortium, is addressing these challenges by harmonizing, sharing, and analyzing data on over 1.8 million women, over 115, 000 of whom have developed breast cancer. The BCRPP is developing a comprehensive tool that will predict breast cancer risk, overall and by subtypes, across major racial and ethnic groups in the United States. This tool incorporates known and emerging risk factors (e.g. reproductive history, anthropometry, smoking, alcohol intake, medication use, mammography, family history, and measured genotypes). In parallel to model building and validation efforts, BCRPP investigators are developing privacy-preserving web and mobile interfaces to deliver the risk tools to patients and clinicians. Here we present descriptive data on participating cohorts (e.g. dates of enrollment, ages at enrollment, length of follow up, numbers of cases by subtype), summarize missing data patterns and our approach to model development and validation that accounts for heterogeneity in missingness patterns across cohorts, and describe data governance procedures and data sharing infrastructure (including pooled and federated analyses, to account for policy limitations on sharing individual data). Descriptive information and procedures for requesting and accessing data are available via the BCRPP data platform (https://epidataplatforms.cancer.gov/bcrpp/). Although originally assembled for risk model development, these data on a large and diverse sample of women with extensive harmonized risk factors and covariates can be a resource to address other outstanding questions in breast cancer epidemiology across time, the lifecourse, and diverse populations. Citation Format: Peter Kraft, Laura Beane-Freeman, Julie Palmer, Ellen O'Meara, Jeanine Genkinger, James Lacey, Thomas Rohan, Lauren Teras, Marian L. Neuhouser, Kala Visvanathan, Celine Vachon, Roger Milne, Christopher Haiman, Yu Chen, Heather Eliassen, Cari Kitahara, Katie O'Brien, Emily White, Garnet Anderson, I-Min Lee, Archie Campbell, Renee Fortner, Ylva Lagerros, Sven Sandin, Mia Gaudet, Montserrat Garcia-Closas, Nilanjan Chatterjee. The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3583.
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Tesfay, Mulu Z. , Ferdous, Khandoker Usran, Shelton, Randal S., Mustafa, Bahaa , Simões, Camila , Moaven, Moaven, Roberts, Lewis R. , Cannon, Martin J. , Bolni, Nagalo, Roberts, Lewis R , Cios, Aleksandra , Post, Steven R. , Kelly, Thomas J. , Borad, Mitesh J. , Basnakian, Alexei G.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 945-945

10.1158/1538-7445.am2025-945 Get It

The global burden of hepatocellular carcinoma (HCC) continues to rise, driven by increasing metabolic risk factors such as nonalcoholic fatty liver disease, obesity, and type II diabetes. Patients with advanced HCC have limited therapeutic options and a dismal prognosis. While recent advancements in combination therapies—including immune checkpoint blockade (ICB) with anti-PD-1/PD-L1 and anti-CTLA-4 agents and anti-angiogenics—have improved survival for some, up to 80% of patients fail to respond, underscoring an unmet need for new strategies. Emerging data indicate a strong association between increased tumor-infiltrating lymphocytes (TILs) and better responses in ICB-treated HCC, suggesting TIL enhancement as a promising approach. However, HCC’s inherent low immunogenicity and immunosuppressive tumor microenvironment (TME) limit the efficacy of current TIL-promoting strategies. Here, we demonstrate that low-dose intratumoral immunotherapy using the trivalent MMR vaccine—composed of live attenuated measles, mumps, and rubella viruses—modulates TME immune infiltration, increases cytotoxic T cell frequency, and delays tumor growth in multiple murine HCC models. Importantly, intratumoral or systemic MMR administration in combination with dual ICB (anti-mPD-1/anti-mCTLA-4) significantly prolongs survival, promoting tumor-specific and memory immune responses in both subcutaneous and orthotopic HCC models. These findings reveal a unique mechanism of vaccine-induced anti-tumor activity, highlighting MMR as a viable, globally accessible option for enhancing immune responses in advanced HCC therapy. Citation Format: Mulu Z. Tesfay,Aleksandra Cios,Khandoker U. Randal S. Shelton,Bahaa Mustafa,Camila C. Simoes,Steven Post,Thomas Kelly,Moaven Moaven,Lewis R. Roberts,Mitesh J. Borad,Martin J. Cannon,Alexei Basnakian,Nagalo Bolni. Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 945.